Finance

Lists
GSK:NYSE
GSK plc
၄၆.၉၂ US$
+၀.၀၂%
(+၀.၀၁၀၀) 1D
၄၇.၁၀ US$
+၀.၃၈% (+၀.၁၈)
Pre-market
Closed: အောက် ၁၂, GMT-၄ ၁၆:၀၀:၀၂  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Mkt. cap
ဋေ ၉.၄၅ ထ
Avg. vol.
၄.၁၅ သန်း
Volume
၂.၈၄ သောင်း
Dividend
၃.၈၇%
Quarterly dividend
၀.၄၅ US$
Ex-dividend date
၂၀၂၆ ဩ ၁၃
P/E ratio
၁၅.၀၅
52-wk high
၆၁.၇၀ US$
52-wk low
၄၂.၈၄ US$
EPS
၃.၁၂ US$
Beta
၀.၂၅
Shares outstanding
၂၁၅.၈၂ ဋေ
No. of employees
၇ သောင်း
Mkt. cap
ဋေ ၉.၄၅ ထ
Avg. vol.
၄.၁၅ သန်း
Volume
၂.၈၄ သောင်း
Dividend
၃.၈၇%
Quarterly dividend
၀.၄၅ US$
Ex-dividend date
၂၀၂၆ ဩ ၁၃
P/E ratio
၁၅.၀၅
52-wk high
၆၁.၇၀ US$
52-wk low
၄၂.၈၄ US$
EPS
၃.၁၂ US$
Beta
၀.၂၅
Shares outstanding
၂၁၅.၈၂ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ နာရီ
JPMorgan keeps GSK stock Underweight at GBp 1,700.00 target
Kalkine Media
Kalkine Media
·
ပြီးခဲ့သည့် ၂ နာရီ
GSK PDMRs Purchase Shares Through Dividend Reinvestment on October 8, 2026
Stock Titan
Stock Titan
·
ပြီးခဲ့သည့် ၃ နာရီ
Dividend reinvestment gives Iain Whyte 1,182 GSK (GSK) shares at £17.5904 each.
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၅ နာရီ
Insider share acquisitions support GSK stock as upward price move persists
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
Sector-
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current ၄၆.၉၂ US$
၇၀.၀၀ US$ (+၄၉.၁၉%)
Average
၆၅.၀၀ US$ (+၃၈.၅၃%)
Lowest
၆၀.၀၀ US$ (+၂၇.၈၈%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Berenberg Bank
Buy
Upgraded
၆၀.၀၀ US$
+၂၇.၉%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
၇၀.၀၀ US$
+၄၉.၂%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Michael Leuchten
Jefferies
Buy
Maintained
၆၇.၁၀ US$
+၄၃%
05/29/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Last report
၂၀၂၆ ဇူ ၂၈
Fiscal period
Q2 2026
၁.၃၄ £ / ၁.၂၅ £
+၇.၂၄%beat
Revenue / Est. (GBP)
၈၄၀.၉၀ ဋေ / ၈၃၂.၃၀ ဋေ
+၁.၀၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၈၅၄.၇၀ ဋေ
၈၆၁.၈၀ ဋေ
၇၆၂.၉၀ ဋေ
၈၄၀.၉၀ ဋေ
Cost of goods sold
၂၂၃.၉၀ ဋေ
၂၆၁.၇၀ ဋေ
၁၈၇.၃၀ ဋေ
၂၀၇.၂၀ ဋေ
Cost of revenue
၂၂၃.၉၀ ဋေ
၂၆၁.၇၀ ဋေ
၁၈၇.၃၀ ဋေ
၂၀၇.၂၀ ဋေ
Research and development expenses
၁၅၇.၅၀ ဋေ
၂၁၃.၈၀ ဋေ
၁၅၁.၈၀ ဋေ
၁၇၄.၇၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂၁၆.၂၀ ဋေ
၂၆၆.၆၀ ဋေ
၂၀၈.၅၀ ဋေ
၂၁၉.၂၀ ဋေ
Operating expense
၃၂၂.၆၀ ဋေ
၄၃၇.၀၀ ဋေ
၂၉၈.၈၀ ဋေ
၃၇၃.၅၀ ဋေ
Total operating expenses
၅၄၆.၅၀ ဋေ
၆၉၈.၇၀ ဋေ
၄၈၆.၁၀ ဋေ
၅၈၀.၇၀ ဋေ
Operating income
၃၀၈.၂၀ ဋေ
၁၆၃.၁၀ ဋေ
၂၇၆.၈၀ ဋေ
၂၆၀.၂၀ ဋေ
Other non operating income
-
-၂.၁၀ ကုဋေ
-
-
EBT including unusual items
၂၄၅.၆၀ ဋေ
၉၅.၀၀ ကုဋေ
၂၁၄.၄၀ ဋေ
၃၅.၄၀ ကုဋေ
EBT excluding unusual items
၂၉၄.၅၀ ဋေ
၁၄၈.၁၀ ဋေ
၂၆၁.၉၀ ဋေ
၂၄၇.၅၀ ဋေ
Income tax expense
၃၁.၂၀ ကုဋေ
၂၂.၃၀ ကုဋေ
၃၀.၅၀ ကုဋေ
-၁၉.၉၀ ကုဋေ
Effective tax rate
၁၂.၇၀%
၂၃.၄၇%
၁၄.၂၃%
-၅၆.၂၁%
Other operating expenses
-၅၁.၁၀ ကုဋေ
-၄၃.၄၀ ကုဋေ
-၆၁.၅၀ ကုဋေ
-၂၀.၄၀ ကုဋေ
Net income
၂၀၁.၃၀ ဋေ
၆၃.၆၀ ကုဋေ
၁၇၃.၇၀ ဋေ
၄၃.၅၀ ကုဋေ
Net profit margin
၂၃.၅၅%
၇.၃၈%
၂၂.၇၇%
၅.၁၇%
Earnings per share
၀.၅၅
-
-
-
Interest and investment income
၂.၆၀ ကုဋေ
၁.၇၀ ကုဋေ
၂.၂၀ ကုဋေ
၅.၈၀ ကုဋေ
Interest expense
-၁၆.၇၀ ကုဋေ
-၁၄.၅၀ ကုဋေ
-၁၆.၇၀ ကုဋေ
-၁၈.၂၀ ကုဋေ
Net interest expenses
-၁၄.၁၀ ကုဋေ
-၁၂.၈၀ ကုဋေ
-၁၄.၅၀ ကုဋေ
-၁၂.၄၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၃၈၂.၀၀ ဋေ
၂၆၈.၉၀ ဋေ
၃၂၃.၁၀ ဋေ
၂၈၂.၅၀ ဋေ
Gain or loss from assets sale
-
-၄.၀၀ ကုဋေ
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ